Wednesday, 4 April 2012

Flavoxate Hydrochloride


Class: Genitourinary Smooth Muscle Relaxants
ATC Class: G04BD02
VA Class: GU201
Chemical Name: 2-piperidinoethyl 3-methyl-4-oxo-2-phenyl-4H-1-benzopyran-8-carboxylate hydrochloride
CAS Number: 3717-88-2
Brands: Urispas

Introduction

Genitourinary antispasmodic.a b


Uses for Flavoxate Hydrochloride


Overactive Bladder


Symptomatic relief of dysuria, urgency, nocturia, suprapubic pain, frequency and incontinence associated with cystitis, prostatitis, urethritis, urethrocystitis, or urethrotrigonitis. b Not indicated as definitive treatment, but is compatible with drugs used for treatment of urinary tract infections.a


Has not been shown to be more effective in the treatment of these conditions than antimuscarinic agents.a


Flavoxate Hydrochloride Dosage and Administration


Administration


Oral Administration


Administer orally 3 or 4 times daily.a b


Dosage


Available as flavoxate hydrochloride; dosage expressed in terms of the salt.b


Pediatric Patients


Oral

Children ≥12 years of age: 100 or 200 mg 3 or 4 times daily. a b May reduce dosage as symptoms improve.a b


Adults


Oral

100 or 200 mg 3 or 4 times daily. a b May reduce dosage as symptoms improve.a b


Special Populations


No special population dosage recommendations at this time.b


Cautions for Flavoxate Hydrochloride


Contraindications



  • Pyloric or duodenal obstruction. a b




  • Obstructive intestinal lesions or ileus.a b




  • Achalasia.a b




  • GI hemorrhage.a b




  • Obstructive uropathies of the lower urinary tract.a b



Warnings/Precautions


Warnings


Glaucoma

Use with caution in patients with suspected glaucoma. a b


Specific Populations


Pregnancy

Category B.b


Lactation

Not known whether flavoxate is distributed into milk.a b Caution if used in nursing women.b


Pediatric Use

Safety and efficacy not established in children <12 years of age. a b


Geriatric Use

Possible increased incidence of mental confusion compared with younger adults.b


Common Adverse Effects


Nausea, vomiting, dry mouth, vertigo, headache, mental confusion, drowsiness, nervousness, blurred vision.b


Interactions for Flavoxate Hydrochloride


No formal drug interaction studies to date.a b


Flavoxate Hydrochloride Pharmacokinetics


Absorption


Bioavailability


Appears to be well absorbed from the GI tract. a


Onset


Following oral administration in healthy males, onset of action was 55 minutes.a


Duration


Following oral administration in healthy males, peak effect occurred at 112 minutes.a


Distribution


Extent


Not known whether flavoxate is distributed into milk.a


Elimination


Elimination Route


57% of an oral dose of flavoxate is excreted in urine within 24 hours.a b


Special Populations


Not known whether flavoxate is dialyzable.a


Stability


Storage


Oral


Tablets

15–30°C.a b


ActionsActions



  • Exerts a direct spasmolytic (papaverine-like) action on smooth muscle of the urinary tract.a b




  • Increases urinary bladder capacity in patients with evidence of bladder spasticity, possibly as a result of action on the detrusor muscle.a



Advice to Patients



  • Risk of drowsiness or blurred vision; use caution when driving, operating machinery, or participating in activities where alertness is required.b




  • Importance of women informing their clinician if they are or plan to become pregnant or plan to breast-feed.b




  • Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs, as well as any concomitant illnesses.b




  • Importance of informing patients of other important precautionary information.b (See Cautions.)



Preparations


Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.


* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name













Flavoxate Hydrochloride

Routes



Dosage Forms



Strengths



Brand Names



Manufacturer



Oral



Tablets, film-coated



100 mg*



Urispas



Ortho-McNeil


Comparative Pricing


This pricing information is subject to change at the sole discretion of DS Pharmacy. This pricing information was updated 03/2011. Actual costs to patients will vary depending on the use of specific retail or mail-order locations and health insurance copays.


Flavoxate HCl 100MG Tablets (GLOBAL PHARMACEUTICAL CORP): 100/$99.99 or 300/$279.96


Urispas 100MG Tablets (MCNEIL): 28/$51.99 or 84/$145.97



Disclaimer

This report on medications is for your information only, and is not considered individual patient advice. Because of the changing nature of drug information, please consult your physician or pharmacist about specific clinical use.


The American Society of Health-System Pharmacists, Inc. and Drugs.com represent that the information provided hereunder was formulated with a reasonable standard of care, and in conformity with professional standards in the field. The American Society of Health-System Pharmacists, Inc. and Drugs.com make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information and specifically disclaims all such warranties. Users are advised that decisions regarding drug therapy are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and the information is provided for informational purposes only. The entire monograph for a drug should be reviewed for a thorough understanding of the drug's actions, uses and side effects. The American Society of Health-System Pharmacists, Inc. and Drugs.com do not endorse or recommend the use of any drug. The information is not a substitute for medical care.

AHFS Drug Information. © Copyright, 1959-2011, Selected Revisions September 2007. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.




References



a. AHFS drug information 2004. McEvoy GK, ed. Flavoxate. Bethesda, MD: American Society of Health-System Pharmacists; 2007: 3600-1.



b. Ortho-McNeil Pharmaceutical, Inc. Urispas (flavoxate hydrochloride) prescribing and patient information. Raritan, NJ; 2004 Aug.



More Flavoxate Hydrochloride resources


  • Flavoxate Hydrochloride Side Effects (in more detail)
  • Flavoxate Hydrochloride Dosage
  • Flavoxate Hydrochloride Use in Pregnancy & Breastfeeding
  • Drug Images
  • Flavoxate Hydrochloride Drug Interactions
  • Flavoxate Hydrochloride Support Group
  • 1 Review for Flavoxate Hydrochloride - Add your own review/rating


  • Flavoxate MedFacts Consumer Leaflet (Wolters Kluwer)

  • Flavoxate Prescribing Information (FDA)

  • Flavoxate Professional Patient Advice (Wolters Kluwer)

  • Urispas Prescribing Information (FDA)

  • flavoxate Concise Consumer Information (Cerner Multum)

  • flavoxate Advanced Consumer (Micromedex) - Includes Dosage Information



Compare Flavoxate Hydrochloride with other medications


  • Dysuria
  • Overactive Bladder
  • Urinary Incontinence

No comments:

Post a Comment